Dechra Pharmaceuticals ( LON:DPH – Get Rating ) ‘s stock had its 'buy' rating reiterated by equities researchers at Numis Securities in a research report issued to clients and investors on Monday, Digital Look reports. They currently have a GBX 4,000 ($49.75) price target on the stock. Numis Securities' price target indicates a potential upside of 26.02% from the company's current price. A number of other research analysts have also recently commented on the company. Jefferies Financial Group restated a 'buy' rating and set a GBX 3,112 ($38.

https://www.dailypolitical.com/2023/05/22/numis-securities-reiterates-buy-rating-for-dechra-pharmaceuticals-londph.html

#dailypolitical